arrow_back

search

search

sort

next_plan

Microbiome, in autism and covid

expand_more

141K views1 year ago

thumb_upLike

thumb_downDislike

library_addSave

flagReport

Dr. John Campbell check_circle

2K subscribers

Dr Sabine Hazan, Doctor and Gastroenterologist of over 30 years is an expert on the gut microbiome. She has conducted over 200 clinical research trials. Her Research Genetic Sequence Laboratory is spear-heading studies on the gut-microbiome, cataloguing all that can be found.

physiology,nursing,NCLEX,health,disease,biology,medicine,nurse education,medical education,pathophysiology,campbell,human biology,human body,mEdgatHJ7gg,, Health,Society, channel_UCF9IOB2TExg3QIBupFtBDxg, video_mEdgatHJ7gg

vid:262917

Comments0

unfold_more

Useless eaters like me

Dr. John Campbell check_circle

101K views 1 year ago

Insulin resistance with Dr. Dhand

Dr. John Campbell check_circle

95K views 1 year ago

Vaccine injuries, full version

Dr. John Campbell check_circle

82K views 1 year ago

Great interview with Jimmy Dore

Dr. John Campbell check_circle

47K views 1 year ago

mRNA in our cells (part 2)

Dr. John Campbell check_circle

56K views 1 year ago

keyboard_arrow_left

Alex Jones Show

Bannons War Room

navigate_next

Ivermectin research

Dr. John Campbell check_circle

167K views 1 year ago

,With Professor Colleen Aldous Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part II: Causal inference using the Bradford Hill criteria https://www.jstage.jst.go.jp/article/antibiotics/78/1/78_35/_pdf/-char/en We continue the critical appraisal of three published case series of 119 COVID-19 patients with hypoxemia, treated in the United States, Zimbabwe, and Nigeria with similar ivermectin-based multidrug treatments, to assess the available evidence supporting a causal relationship between treatment and reduction in hospitalizations and mortality. A narrative review was conducted to assess the Bradford Hill criteria for a causal association. We used a previously proposed refinement of the Bradford Hill criteria that reorganized them into three categories of direct, mechanistic, and parallel evidence. The efficacy of the two most aggressive ivermectin-based multidrug protocols is supported by the Bradford Hill criteria for temporality, strength of association, biological gradient, biological plausibility, coherence, consistency, and analogy. The causal relation between the treatment of hypoxemic COVID-19 patients using these protocols and the reduction in hospitalizations and mortality is supported as an inference to the best explanation. Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part I. Evidence supporting the strength of association https://faculty.utrgv.edu/eleftherios.gkioulekas/papers/032-c19-ivm-oxygen.pdf On March 11, 2020, Coronavirus Disease 2019 (COVID-19), the disease caused by the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) [1]. Worldwide, 768,187,096 confirmed cases of COVID-19 and 6,945,714 deaths have been reported to the WHO as of June 21 2023, amounting to an average Case Fatality Rate (CFR) of 0.9% [2]. During 2020, while several governments and public health agencies were focused on contagion control and in-hospital patient care, several medical doctors from all around the world innovated and discovered early outpatient multidrug treatments using several repurposed medications in combination [3–15]. In the United States, several independent efforts coalesced into the formulation of a sequenced multidrug protocol [10, Fig. 3] (hereafter, McCullough protocol), which is based on the pathophysiological understanding of COVID-19 as a triphasic illness with three overlapping phases: (1) viral proliferation; (2) hyperinflammatory cytokine storm (COVID-19 pneumonia); and (3) thrombosis. McCullough’s protocol proposed a combination antiviral therapy for treating the viral proliferation phase, immunomodulators for treating the cytokine storm, and antiplatelet agents and antithrombotics for handling the thrombotic stage, based on risk stratification and how the disease presents in each individual patient. Thus, the McCullough protocol is an algorithmic treatment using sequenced multiple drugs in combination and customized to the individual patient and their response to treatment; no single drug is necessary nor sufficient to achieve treatment efficacy towards reducing hospitalizations and deaths. A recently published update of the McCullough protocol [16, Fig. 3] introduced some adjustments including virucidal nasal washes and oral gargles [17–24]. A large case series of 869 high-risk patients [25, 26], who were treated using an early version of the McCullough protocol, has been compared against population-level and historical controls [27], showing the existence of efficacy with respect to the reduction of mortality and hospitalizations, which is also resilient with respect to random selection bias, provided that patients are treated early enough within the first 3 to 5 days from the onset of illness. Indeed, an earlier study by Fazio et al.[28] showed that the ideal window of opportunity for initiating an effective early outpatient treatment of COVID-19 to prevent hospitalization is approximately within the first 3 days.

Cancer free after mushroom

Dr. John Campbell check_circle

215K views 1 year ago

Increased cancers after mRNA vaccines

Dr. John Campbell check_circle

177K views 1 year ago

,COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province https://pubmed.ncbi.nlm.nih.gov/40881928/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12381369/ https://www.thefocalpoints.com/p/breaking-first-population-wide-study The rate of first hospitalization for cancer of any site Unvaccinated group: 0.85% Vaccinated group (one or more doses): 1.15% N = 296,015 population Hospital admission with a cancer diagnosis, 3,124 (p less than 0.001). Vaccination with at least one dose Colon-rectal cancer HR: 1.34 Breast cancer HR: 1.54 Bladder cancer HR: 1.62 After three or more vaccine doses Breast cancer HR: 1.36 Bladder cancer HR: 1.43 All significant After one dose (180 days after) Rate of first hospital admissions for cancers All cancers: up 23% significant Colorectal: up 34% significant Lung: down = 10% Breast: up 54% significant Uterine: up = 75% Ovarian: up = 65% Prostate: up = 1% Bladder: up 62% significant Thyroid: up =58% Haematological: up = 33% After three dose (180 days after administration of third dose) All cancers: up = 9% Colorectal: up = 14% Lung: down = 5% Breast: up=36% significant Uterine: up = 20% Ovarian: up = 86% Prostate: down = 3% Bladder: up=43% significant Thyroid: down = 3% Haematological: up = 5% More about the study Population-wide cohort analysis Evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status. National Health System official data, entire population, Pescara province, Italy Followed from June 2021 (six months after the first vaccination) to December 2023. 296,015 residents aged ≥11 years Hospital admission with a cancer diagnosis, 3,124 16.6% were unvaccinated 83.3% received ≥1 dose 62.2% ≥3 doses. Compared with the unvaccinated, those receiving ≥1 dose showed a significantly lower likelihood of all-cause death Cancer hospitalization was significant only among the subjects with no previous SARS-CoV-2 infection Some cancer risks went down after 1 year (relative to 180 days) (But breast, ovarian and bladder went up at one year relative to 180 days after 1 vaccine dose) Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary.

Massive DNA contamination

Dr. John Campbell check_circle

189K views 1 year ago

,Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada https://pubmed.ncbi.nlm.nih.gov/40913499/ 32 vials representing 16 unique vaccine lots. These data demonstrate the presence of billions to hundreds of billions of DNA molecules per dose in the modRNA COVID-19 products tested. All products tested exceeded the guidelines for residual DNA set by the FDA and WHO of 10ng/dose by 36–627-fold. Total DNA in all vials tested Exceeded the regulatory limit for residual DNA set by the US Food & Drug Administration (FDA) and the World Health Authorization (WHO) by: Pfizer: 36-153-fold Moderna: 112-627-fold 3 Pfizer vials exceeded the regulatory limit for the SV40 promoter-enhancer-ori (p53) The PCR results for the most recent XBB.1.5 Moderna and Pfizer vaccines suggest that DNA residues have not been reduced from previous vaccine versions. Pfizer, Total DNA ranged 371-1,548 ng/dose Moderna, 1,130-6,280 ng/dose Specific DNA of multiple plasmid DNA targets Pfizer ranged 0.22-7.28 ng/dose Moderna 0.01-0.78 ng/dose for Moderna. The SV40 promoter-enhancer-ori(0.25-23.72 ng/dose) was only detected in Pfizer vials. Sequencing of one vial Mean DNA length, 214 bp Maximum length, 3.5 kb Presence of 1.23 × 108 to 1.60 × 1011 plasmid DNA fragments per dose encapsulated in lipid nanoparticles. Our findings extend existing concerns about vaccine safety and call into question the relevance of guidelines conceived before the introduction of efficient transfection using LNPs. This work highlights the need for regulators and industry to adhere to the precautionary principle and provide sufficient and transparent evidence that products are safe and effective, and disclose the details of their composition and method of manufacture. For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Rationale for study Manufacturing nucleoside-modified mRNA for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of mRNA vaccines, suggesting that the removal of residual DNA template is problematic. Therefore, we quantified the DNA load in a limited number of Pfizer-BioNTech and Moderna COVID-19 modRNA vaccine vials using two independent methods. This study emphasizes the importance of methodological considerations when quantifying residual plasmid DNA in modRNA products, considering increased LNP transfection efficiency, and cumulative dosing presents significant and unquantified risks to human health.

Natural medicine, Flax seed

Dr. John Campbell check_circle

399K views 1 year ago

,This research report found Flax seeds reduced high blood pressure, body mass index and total cholesterol. New series on natural approaches to health with well knowh physician Dr Suneel Dhand. Effects of flaxseed on blood pressure, body mass index, and total cholesterol in hypertensive patients: A randomized clinical trial, 2022, Iran https://www.sciencedirect.com/science/article/abs/pii/S1550830721000938 https://pubmed.ncbi.nlm.nih.gov/34119421/ Study was conducted in hypertensive patients to determine the effects of flaxseed supplementation on body mass index (BMI), blood pressure, and total cholesterol levels in patients with hypertension. Methods Fully blind study, 12 weeks age range of 35 to 70 years, Randomized to 3 groups receiving 10 g (n = 45) 30 g (n = 45) of flaxseed supplementation Placebo (wheat) (n = 45) 12 weeks Checked for other variables such as diet and physical activity Results For the 30-g group Mean systolic BP started at 148.38 Over the 12 weeks it decreased by an average of 13.38 mmHg Ended up at an average of 135.00 (p = 0.001) (compared to a 1.72 unit increase in the placebo group, wheat) Still in the 30g group, 30 g group DBP started at 86.20 Over the 12 weeks it decreased by an average of 5.6 mmHg Down to an average of 80.6 mmHg (p = 0.001) (compared to a 2.39 unit increase in the placebo group) For the 10g group SBP reduced by 9.86 mmHg DBP reduction in 10g group, 6.69 BMI For the 30 g group BMI decreased by 0.86 units (compared to reduction of 0.06 units in the placebo group) The mean BMI decreased from 29.19 to 28.33 BMI value (p less than 0.001). Total cholesterol 30 g group, decreased by 20.4 units (compared to 11.86 units in the placebo group) Mean total cholesterol decreased from 210.73 to 190.33 (p = 0.032) Mechanisms Flaxseed is rich in good fats, antioxidants, and fiber (Lignan content, which is a powerful antioxidant) Improves plasma lipid profile, plasma trans-fatty acid concentrations, atherogenicity, glycemia, and pro-inflammatory compounds Flaxseed is one of the richest plant sources of omega-3 fatty acids and ALA, (alpha-linolenic acid, the oil that forms 41% of the total weight of a seed) Consistent studies The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial https://pubmed.ncbi.nlm.nih.gov/31980022/ Effect of Flaxseed Powder on Cardiovascular Risk Factor in Dyslipidemic and Hypertensive Patients https://pmc.ncbi.nlm.nih.gov/articles/PMC6941378/ The effect of flaxseed supplementation on body weight and body composition: a systematic review and meta-analysis of 45 randomized placebo-controlled trials https://onlinelibrary.wiley.com/doi/10.1111/obr.12550

Wow, my Vit D is low

Dr. John Campbell check_circle

306K views 1 year ago

Vaccines and fertility

Dr. John Campbell check_circle

66K views 1 year ago

Population control

Dr. John Campbell check_circle

147K views 1 year ago

Microbiome, in autism and covid

Dr. John Campbell check_circle

141K views 1 year ago

RSV vaccine 'paused'

Dr. John Campbell check_circle

83K views 1 year ago

Spike and disease

Dr. John Campbell check_circle

293K views 1 year ago

DNA scientist reveals contamination

Dr. John Campbell check_circle

40K views 1 year ago

,With eminent DNA scientist and virologist, Dr. David J. Speicher. Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada https://pubmed.ncbi.nlm.nih.gov/40913499/ 32 vials representing 16 unique vaccine lots. These data demonstrate the presence of billions to hundreds of billions of DNA molecules per dose in the modRNA COVID-19 products tested. All products tested exceeded the guidelines for residual DNA set by the FDA and WHO of 10ng/dose by 36–627-fold. Total DNA in all vials tested Exceeded the regulatory limit for residual DNA set by the US Food & Drug Administration (FDA) and the World Health Authorization (WHO) by: Pfizer: 36-153-fold Moderna: 112-627-fold 3 Pfizer vials exceeded the regulatory limit for the SV40 promoter-enhancer-ori (p53) The PCR results for the most recent XBB.1.5 Moderna and Pfizer vaccines suggest that DNA residues have not been reduced from previous vaccine versions. Pfizer, Total DNA ranged 371-1,548 ng/dose Moderna, 1,130-6,280 ng/dose Specific DNA of multiple plasmid DNA targets Pfizer ranged 0.22-7.28 ng/dose Moderna 0.01-0.78 ng/dose for Moderna. The SV40 promoter-enhancer-ori(0.25-23.72 ng/dose) was only detected in Pfizer vials. Sequencing of one vial Mean DNA length, 214 bp Maximum length, 3.5 kb Presence of 1.23 × 108 to 1.60 × 1011 plasmid DNA fragments per dose encapsulated in lipid nanoparticles. Our findings extend existing concerns about vaccine safety and call into question the relevance of guidelines conceived before the introduction of efficient transfection using LNPs. This work highlights the need for regulators and industry to adhere to the precautionary principle and provide sufficient and transparent evidence that products are safe and effective, and disclose the details of their composition and method of manufacture. For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Rationale for study Manufacturing nucleoside-modified mRNA for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of mRNA vaccines, suggesting that the removal of residual DNA template is problematic. Therefore, we quantified the DNA load in a limited number of Pfizer-BioNTech and Moderna COVID-19 modRNA vaccine vials using two independent methods. This study emphasizes the importance of methodological considerations when quantifying residual plasmid DNA in modRNA products, considering increased LNP transfection efficiency, and cumulative dosing presents significant and unquantified risks to human health.

White clots in 2025

Dr. John Campbell check_circle

178K views 1 year ago

Dr. John Campbell check_circle

136K views 1 year ago

Madness of Crowds

Dr. John Campbell check_circle

214K views 1 year ago